ID   IKKA_HUMAN              Reviewed;         745 AA.
AC   O15111; O14666; Q13132; Q5W0I4; Q92467;
DT   01-JUN-2001, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 2.
DT   10-MAY-2017, entry version 191.
DE   RecName: Full=Inhibitor of nuclear factor kappa-B kinase subunit alpha;
DE            Short=I-kappa-B kinase alpha;
DE            Short=IKK-A;
DE            Short=IKK-alpha;
DE            Short=IkBKA;
DE            Short=IkappaB kinase;
DE            EC=2.7.11.10;
DE   AltName: Full=Conserved helix-loop-helix ubiquitous kinase;
DE   AltName: Full=I-kappa-B kinase 1;
DE            Short=IKK1;
DE   AltName: Full=Nuclear factor NF-kappa-B inhibitor kinase alpha;
DE            Short=NFKBIKA;
DE   AltName: Full=Transcription factor 16;
DE            Short=TCF-16;
GN   Name=CHUK; Synonyms=IKKA, TCF16;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], MUTAGENESIS OF LYS-44, AND VARIANT
RP   ILE-268.
RC   TISSUE=T-cell;
RX   PubMed=9244310; DOI=10.1016/S0092-8674(00)80344-X;
RA   Regnier C.H., Song H.Y., Gao X., Goeddel D.V., Cao Z., Rothe M.;
RT   "Identification and characterization of an IkappaB kinase.";
RL   Cell 90:373-383(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, AND VARIANT
RP   ILE-268.
RX   PubMed=9252186; DOI=10.1038/41493;
RA   DiDonato J.A., Hayakawa M., Rothwarf D.M., Zandi E., Karin M.;
RT   "A cytokine-responsive IkappaB kinase that activates the transcription
RT   factor NF-kappaB.";
RL   Nature 388:548-554(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, AND MUTAGENESIS
RP   OF LYS-44 AND SER-176.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=9346484; DOI=10.1126/science.278.5339.860;
RA   Mercurio F., Zhu H., Murray B.W., Shevchenko A., Bennett B.L.,
RA   Li J.W., Young D.B., Barbosa M., Mann M., Manning A., Rao A.;
RT   "IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-
RT   kappaB activation.";
RL   Science 278:860-866(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ILE-268.
RC   TISSUE=Heart;
RX   PubMed=9813230; DOI=10.1016/S0378-1119(98)00462-4;
RA   Hu M.C.-T., Wang Y.-P.;
RT   "IkappaB kinase-alpha and -beta genes are coexpressed in adult and
RT   embryonic tissues but localized to different human chromosomes.";
RL   Gene 222:31-40(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ILE-268.
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 32-745, AND VARIANT ILE-268.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=8777433;
RA   Connelly M.A., Marcu K.B.;
RT   "CHUK, a new member of the helix-loop-helix and leucine zipper
RT   families of interacting proteins, contains a serine-threonine kinase
RT   catalytic domain.";
RL   Cell. Mol. Biol. Res. 41:537-549(1995).
RN   [8]
RP   PROTEIN SEQUENCE OF 169-181, INACTIVATION BY YERSINIA YOPJ (MICROBIAL
RP   INFECTION), ACETYLATION AT THR-179 (MICROBIAL INFECTION), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=17116858; DOI=10.1073/pnas.0608995103;
RA   Mittal R., Peak-Chew S.Y., McMahon H.T.;
RT   "Acetylation of MEK2 and I kappa B kinase (IKK) activation loop
RT   residues by YopJ inhibits signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:18574-18579(2006).
RN   [9]
RP   IDENTIFICATION IN A COMPLEX WITH IKBKB; NFKBIA; RELA; IKBKAP AND
RP   MAP3K14.
RX   PubMed=9751059; DOI=10.1038/26254;
RA   Cohen L., Henzel W.J., Baeuerle P.A.;
RT   "IKAP is a scaffold protein of the IkappaB kinase complex.";
RL   Nature 395:292-296(1998).
RN   [10]
RP   PHOSPHORYLATION AT SER-176, AND MUTAGENESIS OF SER-176; THR-179 AND
RP   SER-180.
RX   PubMed=9520446; DOI=10.1073/pnas.95.7.3792;
RA   Ling L., Cao Z., Goeddel D.V.;
RT   "NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of
RT   Ser-176.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:3792-3797(1998).
RN   [11]
RP   PHOSPHORYLATION AT THR-23, AND MUTAGENESIS OF THR-23.
RX   PubMed=10485710; DOI=10.1038/43466;
RA   Ozes O.N., Mayo L.D., Gustin J.A., Pfeffer S.R., Pfeffer L.M.,
RA   Donner D.B.;
RT   "NF-kappaB activation by tumour necrosis factor requires the Akt
RT   serine-threonine kinase.";
RL   Nature 401:82-85(1999).
RN   [12]
RP   INTERACTION WITH IKBKB.
RX   PubMed=10195894; DOI=10.1126/science.284.5412.309;
RA   Delhase M., Hayakawa M., Chen Y., Karin M.;
RT   "Positive and negative regulation of IkappaB kinase activity through
RT   IKKbeta subunit phosphorylation.";
RL   Science 284:309-313(1999).
RN   [13]
RP   IKK PHOSPHORYLATION.
RX   PubMed=9819420; DOI=10.1128/MCB.18.12.7336;
RA   Nemoto S., DiDonato J.A., Lin A.;
RT   "Coordinate regulation of IkappaB kinases by mitogen-activated protein
RT   kinase kinase kinase 1 and NF-kappaB-inducing kinase.";
RL   Mol. Cell. Biol. 18:7336-7343(1998).
RN   [14]
RP   REVIEW.
RX   PubMed=10712233;
RA   Jobin C., Sartor R.B.;
RT   "The I kappa B/NF-kappa B system: a key determinant of mucosal
RT   inflammation and protection.";
RL   Am. J. Physiol. 278:C451-C462(2000).
RN   [15]
RP   SUBUNIT OF A COMPLEX CONTAINING CREBBP; NCOA2; NCOA3; IKBKB AND IKBKG.
RX   PubMed=11971985; DOI=10.1128/MCB.22.10.3549-3561.2002;
RA   Wu R.-C., Qin J., Hashimoto Y., Wong J., Xu J., Tsai S.Y., Tsai M.-J.,
RA   O'Malley B.W.;
RT   "Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) coactivator
RT   activity by I kappa B kinase.";
RL   Mol. Cell. Biol. 22:3549-3561(2002).
RN   [16]
RP   COMPOSITION OF THE IKK COMPLEX.
RX   PubMed=12612076; DOI=10.1128/MCB.23.6.2029-2041.2003;
RA   Tegethoff S., Behlke J., Scheidereit C.;
RT   "Tetrameric oligomerization of IkappaB kinase gamma (IKKgamma) is
RT   obligatory for IKK complex activity and NF-kappaB activation.";
RL   Mol. Cell. Biol. 23:2029-2041(2003).
RN   [17]
RP   SUBCELLULAR LOCATION, AND FUNCTION IN PHOSPHORYLATION OF HISTONE H3.
RX   PubMed=12789342; DOI=10.1038/nature01576;
RA   Yamamoto Y., Verma U.N., Prajapati S., Kwak Y.T., Gaynor R.B.;
RT   "Histone H3 phosphorylation by IKK-alpha is critical for cytokine-
RT   induced gene expression.";
RL   Nature 423:655-659(2003).
RN   [18]
RP   FUNCTION, AND INTERACTION WITH FOXO3.
RX   PubMed=15084260; DOI=10.1016/S0092-8674(04)00302-2;
RA   Hu M.C., Lee D.F., Xia W., Golfman L.S., Ou-Yang F., Yang J.Y.,
RA   Zou Y., Bao S., Hanada N., Saso H., Kobayashi R., Hung M.C.;
RT   "IkappaB kinase promotes tumorigenesis through inhibition of forkhead
RT   FOXO3a.";
RL   Cell 117:225-237(2004).
RN   [19]
RP   INTERACTION WITH NALP2.
RX   PubMed=15456791; DOI=10.1074/jbc.M406741200;
RA   Bruey J.-M., Bruey-Sedano N., Newman R., Chandler S., Stehlik C.,
RA   Reed J.C.;
RT   "PAN1/NALP2/PYPAF2, an inducible inflammatory mediator that regulates
RT   NF-kappaB and caspase-1 activation in macrophages.";
RL   J. Biol. Chem. 279:51897-51907(2004).
RN   [20]
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=15173580; DOI=10.1073/pnas.0402851101;
RA   Witherow D.S., Garrison T.R., Miller W.E., Lefkowitz R.J.;
RT   "beta-Arrestin inhibits NF-kappaB activity by means of its interaction
RT   with the NF-kappaB inhibitor IkappaBalpha.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:8603-8607(2004).
RN   [21]
RP   INTERACTION WITH MAVS.
RX   PubMed=16177806; DOI=10.1038/nature04193;
RA   Meylan E., Curran J., Hofmann K., Moradpour D., Binder M.,
RA   Bartenschlager R., Tschopp J.;
RT   "Cardif is an adaptor protein in the RIG-I antiviral pathway and is
RT   targeted by hepatitis C virus.";
RL   Nature 437:1167-1172(2005).
RN   [22]
RP   INTERACTION WITH PIAS1.
RX   PubMed=17540171; DOI=10.1016/j.cell.2007.03.056;
RA   Liu B., Yang Y., Chernishof V., Loo R.R., Jang H., Tahk S., Yang R.,
RA   Mink S., Shultz D., Bellone C.J., Loo J.A., Shuai K.;
RT   "Proinflammatory stimuli induce IKKalpha-mediated phosphorylation of
RT   PIAS1 to restrict inflammation and immunity.";
RL   Cell 129:903-914(2007).
RN   [23]
RP   FUNCTION IN PHOSPHORYLATION OF CREBBP.
RX   PubMed=17434128; DOI=10.1016/j.molcel.2007.02.019;
RA   Huang W.C., Ju T.K., Hung M.C., Chen C.C.;
RT   "Phosphorylation of CBP by IKKalpha promotes cell growth by switching
RT   the binding preference of CBP from p53 to NF-kappaB.";
RL   Mol. Cell 26:75-87(2007).
RN   [24]
RP   REVIEW, AND DOMAIN.
RX   PubMed=18626576; DOI=10.1007/s12026-008-8025-1;
RA   Solt L.A., May M.J.;
RT   "The IkappaB kinase complex: master regulator of NF-kappaB
RT   signaling.";
RL   Immunol. Res. 42:3-18(2008).
RN   [25]
RP   PHOSPHORYLATION AT THR-23 AND SER-180 BY SGK1.
RX   PubMed=19088076; DOI=10.1074/jbc.M805055200;
RA   Tai D.J., Su C.C., Ma Y.L., Lee E.H.;
RT   "SGK1 phosphorylation of IkappaB Kinase alpha and p300 Up-regulates
RT   NF-kappaB activity and increases N-Methyl-D-aspartate receptor NR2A
RT   and NR2B expression.";
RL   J. Biol. Chem. 284:4073-4089(2009).
RN   [26]
RP   INTERACTION WITH TRAF2.
RX   PubMed=19150425; DOI=10.1016/j.molcel.2008.11.023;
RA   Li S., Wang L., Dorf M.E.;
RT   "PKC phosphorylation of TRAF2 mediates IKKalpha/beta recruitment and
RT   K63-linked polyubiquitination.";
RL   Mol. Cell 33:30-42(2009).
RN   [27]
RP   FUNCTION, AND INTERACTION WITH NLRC5.
RX   PubMed=20434986; DOI=10.1016/j.cell.2010.03.040;
RA   Cui J., Zhu L., Xia X., Wang H.Y., Legras X., Hong J., Ji J., Shen P.,
RA   Zheng S., Chen Z.J., Wang R.F.;
RT   "NLRC5 negatively regulates the NF-kappaB and type I interferon
RT   signaling pathways.";
RL   Cell 141:483-496(2010).
RN   [28]
RP   INVOLVEMENT IN COCOS.
RX   PubMed=20961246; DOI=10.1056/NEJMoa0911698;
RA   Lahtela J., Nousiainen H.O., Stefanovic V., Tallila J., Viskari H.,
RA   Karikoski R., Gentile M., Saloranta C., Varilo T., Salonen R.,
RA   Kestila M.;
RT   "Mutant CHUK and severe fetal encasement malformation.";
RL   N. Engl. J. Med. 363:1631-1637(2010).
RN   [29]
RP   FUNCTION IN MAP3K14 PHOSPHORYLATION.
RX   PubMed=20501937; DOI=10.1126/scisignal.2000778;
RA   Razani B., Zarnegar B., Ytterberg A.J., Shiba T., Dempsey P.W.,
RA   Ware C.F., Loo J.A., Cheng G.;
RT   "Negative feedback in noncanonical NF-kappaB signaling modulates NIK
RT   stability through IKKalpha-mediated phosphorylation.";
RL   Sci. Signal. 3:RA41-RA41(2010).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [31]
RP   FUNCTION IN PHOSPHORYLATION OF TAX1BP1.
RX   PubMed=21765415; DOI=10.1038/ni.2066;
RA   Shembade N., Pujari R., Harhaj N.S., Abbott D.W., Harhaj E.W.;
RT   "The kinase IKKalpha inhibits activation of the transcription factor
RT   NF-kappaB by phosphorylating the regulatory molecule TAX1BP1.";
RL   Nat. Immunol. 12:834-843(2011).
RN   [32]
RP   INTERACTION WITH ZNF268, AND SUBUNIT.
RX   PubMed=23091055; DOI=10.1074/jbc.M112.399923;
RA   Wang W., Guo M., Hu L., Cai J., Zeng Y., Luo J., Shu Z., Li W.,
RA   Huang Z.;
RT   "The zinc finger protein ZNF268 is overexpressed in human cervical
RT   cancer and contributes to tumorigenesis via enhancing NF-kappaB
RT   signaling.";
RL   J. Biol. Chem. 287:42856-42866(2012).
RN   [33]
RP   INTERACTION WITH IFIT5.
RX   PubMed=26334375; DOI=10.1016/j.cellsig.2015.08.018;
RA   Zheng C., Zheng Z., Zhang Z., Meng J., Liu Y., Ke X., Hu Q., Wang H.;
RT   "IFIT5 positively regulates NF-kappaB signaling through synergizing
RT   the recruitment of IkappaB kinase (IKK) to TGF-beta-activated kinase 1
RT   (TAK1).";
RL   Cell. Signal. 27:2343-2354(2015).
RN   [34]
RP   VARIANTS [LARGE SCALE ANALYSIS] CYS-126; ALA-155 AND ILE-268.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 732-745.
RX   PubMed=18462684; DOI=10.1016/j.str.2008.02.012;
RA   Rushe M., Silvian L., Bixler S., Chen L.L., Cheung A., Bowes S.,
RA   Cuervo H., Berkowitz S., Zheng T., Guckian K., Pellegrini M.,
RA   Lugovskoy A.;
RT   "Structure of a NEMO/IKK-associating domain reveals architecture of
RT   the interaction site.";
RL   Structure 16:798-808(2008).
CC   -!- FUNCTION: Serine kinase that plays an essential role in the NF-
CC       kappa-B signaling pathway which is activated by multiple stimuli
CC       such as inflammatory cytokines, bacterial or viral products, DNA
CC       damages or other cellular stresses. Acts as part of the canonical
CC       IKK complex in the conventional pathway of NF-kappa-B activation
CC       and phosphorylates inhibitors of NF-kappa-B on serine residues.
CC       These modifications allow polyubiquitination of the inhibitors and
CC       subsequent degradation by the proteasome. In turn, free NF-kappa-B
CC       is translocated into the nucleus and activates the transcription
CC       of hundreds of genes involved in immune response, growth control,
CC       or protection against apoptosis. Negatively regulates the pathway
CC       by phosphorylating the scaffold protein TAXBP1 and thus promoting
CC       the assembly of the A20/TNFAIP3 ubiquitin-editing complex
CC       (composed of A20/TNFAIP3, TAX1BP1, and the E3 ligases ITCH and
CC       RNF11). Therefore, CHUK plays a key role in the negative feedback
CC       of NF-kappa-B canonical signaling to limit inflammatory gene
CC       activation. As part of the non-canonical pathway of NF-kappa-B
CC       activation, the MAP3K14-activated CHUK/IKKA homodimer
CC       phosphorylates NFKB2/p100 associated with RelB, inducing its
CC       proteolytic processing to NFKB2/p52 and the formation of NF-kappa-
CC       B RelB-p52 complexes. In turn, these complexes regulate genes
CC       encoding molecules involved in B-cell survival and lymphoid
CC       organogenesis. Participates also in the negative feedback of the
CC       non-canonical NF-kappa-B signaling pathway by phosphorylating and
CC       destabilizing MAP3K14/NIK. Within the nucleus, phosphorylates
CC       CREBBP and consequently increases both its transcriptional and
CC       histone acetyltransferase activities. Modulates chromatin
CC       accessibility at NF-kappa-B-responsive promoters by
CC       phosphorylating histones H3 at 'Ser-10' that are subsequently
CC       acetylated at 'Lys-14' by CREBBP. Additionally, phosphorylates the
CC       CREBBP-interacting protein NCOA3. Also phosphorylates FOXO3 and
CC       may regulate this pro-apoptotic transcription factor
CC       (PubMed:15084260). {ECO:0000269|PubMed:12789342,
CC       ECO:0000269|PubMed:15084260, ECO:0000269|PubMed:17434128,
CC       ECO:0000269|PubMed:20434986, ECO:0000269|PubMed:20501937,
CC       ECO:0000269|PubMed:21765415}.
CC   -!- CATALYTIC ACTIVITY: ATP + [I-kappa-B protein] = ADP + [I-kappa-B
CC       phosphoprotein].
CC   -!- ENZYME REGULATION: Activated when phosphorylated and inactivated
CC       when dephosphorylated.
CC   -!- SUBUNIT: Component of the I-kappa-B-kinase (IKK) core complex
CC       consisting of CHUK, IKBKB and IKBKG; probably four alpha/CHUK-
CC       beta/IKBKB dimers are associated with four gamma/IKBKG subunits.
CC       The IKK core complex seems to associate with regulatory or adapter
CC       proteins to form a IKK-signalosome holo-complex (PubMed:10195894,
CC       PubMed:12612076). The IKK complex associates with TERF2IP/RAP1,
CC       leading to promote IKK-mediated phosphorylation of RELA/p65 (By
CC       similarity). Part of a complex composed of NCOA2, NCOA3,
CC       CHUK/IKKA, IKBKB, IKBKG and CREBBP (PubMed:11971985). Part of a
CC       70-90 kDa complex at least consisting of CHUK/IKKA, IKBKB, NFKBIA,
CC       RELA, IKBKAP and MAP3K14 (PubMed:9751059). Directly interacts with
CC       TRPC4AP (By similarity). May interact with TRAF2
CC       (PubMed:19150425). Interacts with NALP2 (PubMed:15456791). May
CC       interact with MAVS/IPS1 (PubMed:16177806). Interacts with ARRB1
CC       and ARRB2 (PubMed:15173580). Interacts with NLRC5; prevents CHUK
CC       phosphorylation and kinase activity (PubMed:20434986). Interacts
CC       with PIAS1; this interaction induces PIAS1 phosphorylation
CC       (PubMed:17540171). Interacts with ZNF268 isoform 2; the
CC       interaction is further increased in a TNF-alpha-dependent manner
CC       (PubMed:23091055). Interacts with FOXO3 (PubMed:15084260).
CC       Interacts with IFIT5; the interaction synergizes the recruitment
CC       of IKK to MAP3K7 and enhances IKK phosphorylation
CC       (PubMed:26334375). {ECO:0000250|UniProtKB:Q60680,
CC       ECO:0000269|PubMed:10195894, ECO:0000269|PubMed:11971985,
CC       ECO:0000269|PubMed:12612076, ECO:0000269|PubMed:15084260,
CC       ECO:0000269|PubMed:15173580, ECO:0000269|PubMed:15456791,
CC       ECO:0000269|PubMed:16177806, ECO:0000269|PubMed:17540171,
CC       ECO:0000269|PubMed:19150425, ECO:0000269|PubMed:20434986,
CC       ECO:0000269|PubMed:23091055, ECO:0000269|PubMed:26334375,
CC       ECO:0000269|PubMed:9751059}.
CC   -!- INTERACTION:
CC       P32121:ARRB2; NbExp=3; IntAct=EBI-81249, EBI-714559;
CC       Q16543:CDC37; NbExp=4; IntAct=EBI-81249, EBI-295634;
CC       P46527:CDKN1B; NbExp=4; IntAct=EBI-81249, EBI-519280;
CC       P03129:E7 (xeno); NbExp=2; IntAct=EBI-81249, EBI-866453;
CC       Q07857:E7 (xeno); NbExp=2; IntAct=EBI-81249, EBI-9690349;
CC       Q6TY28:E7 (xeno); NbExp=2; IntAct=EBI-81249, EBI-9690312;
CC       Q6TY35:E7 (xeno); NbExp=2; IntAct=EBI-81249, EBI-9690239;
CC       Q80901:E7 (xeno); NbExp=2; IntAct=EBI-81249, EBI-9690278;
CC       Q8B5B5:E7 (xeno); NbExp=2; IntAct=EBI-81249, EBI-9690330;
CC       Q13451:FKBP5; NbExp=2; IntAct=EBI-81249, EBI-306914;
CC       P07900:HSP90AA1; NbExp=3; IntAct=EBI-81249, EBI-296047;
CC       O14920:IKBKB; NbExp=15; IntAct=EBI-81249, EBI-81266;
CC       Q9Y6K9:IKBKG; NbExp=21; IntAct=EBI-81249, EBI-81279;
CC       Q92985:IRF7; NbExp=4; IntAct=EBI-81249, EBI-968267;
CC       Q99558:MAP3K14; NbExp=6; IntAct=EBI-81249, EBI-358011;
CC       Q5TCX8:MLK4; NbExp=2; IntAct=EBI-81249, EBI-1057380;
CC       P01106:MYC; NbExp=3; IntAct=EBI-81249, EBI-447544;
CC       P19838:NFKB1; NbExp=3; IntAct=EBI-81249, EBI-300010;
CC       P25963:NFKBIA; NbExp=14; IntAct=EBI-81249, EBI-307386;
CC       Q77M19:P (xeno); NbExp=2; IntAct=EBI-81249, EBI-6149376;
CC       Q04206:RELA; NbExp=2; IntAct=EBI-81249, EBI-73886;
CC       Q86VP1:TAX1BP1; NbExp=2; IntAct=EBI-81249, EBI-529518;
CC       P24772:VACWR196 (xeno); NbExp=3; IntAct=EBI-81249, EBI-4291651;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:12789342}.
CC       Nucleus {ECO:0000269|PubMed:12789342}. Note=Shuttles between the
CC       cytoplasm and the nucleus.
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC   -!- DOMAIN: The kinase domain is located in the N-terminal region. The
CC       leucine zipper is important to allow homo- and hetero-
CC       dimerization. At the C-terminal region is located the region
CC       responsible for the interaction with NEMO/IKBKG.
CC       {ECO:0000269|PubMed:18626576}.
CC   -!- PTM: Phosphorylated by MAP3K14/NIK, AKT and to a lesser extent by
CC       MEKK1, and dephosphorylated by PP2A. Autophosphorylated.
CC   -!- PTM: (Microbial infection) Acetylation of Thr-179 by Yersinia yopJ
CC       prevents phosphorylation and activation, thus blocking the I-
CC       kappa-B signaling pathway. {ECO:0000269|PubMed:17116858}.
CC   -!- DISEASE: Cocoon syndrome (COCOS) [MIM:613630]: A lethal syndrome
CC       characterized by multiple fetal malformations including defective
CC       face and seemingly absent limbs, which are bound to the trunk and
CC       encased under the skin. {ECO:0000269|PubMed:20961246}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family. I-kappa-B kinase subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/chuk/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF012890; AAC51662.1; -; mRNA.
DR   EMBL; AF009225; AAC51671.1; -; mRNA.
DR   EMBL; AF080157; AAD08996.1; -; mRNA.
DR   EMBL; AY652653; AAT49098.1; -; Genomic_DNA.
DR   EMBL; AL138921; CAH72401.1; -; Genomic_DNA.
DR   EMBL; U22512; AAC50713.1; -; mRNA.
DR   CCDS; CCDS7488.1; -.
DR   RefSeq; NP_001269.3; NM_001278.4.
DR   UniGene; Hs.198998; -.
DR   PDB; 3BRT; X-ray; 2.25 A; A/C=732-745.
DR   PDB; 5EBZ; X-ray; 4.50 A; A/B/C/D/E/F/G/H/I/J/K/L=10-660.
DR   PDB; 5TQW; EM; 5.60 A; A/B=10-660.
DR   PDB; 5TQX; EM; 5.40 A; A/B=10-660.
DR   PDB; 5TQY; EM; 5.20 A; A/B=10-660.
DR   PDBsum; 3BRT; -.
DR   PDBsum; 5EBZ; -.
DR   PDBsum; 5TQW; -.
DR   PDBsum; 5TQX; -.
DR   PDBsum; 5TQY; -.
DR   ProteinModelPortal; O15111; -.
DR   SMR; O15111; -.
DR   BioGrid; 107569; 130.
DR   DIP; DIP-27526N; -.
DR   IntAct; O15111; 59.
DR   MINT; MINT-88648; -.
DR   STRING; 9606.ENSP00000359424; -.
DR   BindingDB; O15111; -.
DR   ChEMBL; CHEMBL3476; -.
DR   DrugBank; DB06151; Acetylcysteine.
DR   DrugBank; DB00233; Aminosalicylic Acid.
DR   DrugBank; DB00244; Mesalazine.
DR   DrugBank; DB00795; Sulfasalazine.
DR   GuidetoPHARMACOLOGY; 1989; -.
DR   iPTMnet; O15111; -.
DR   PhosphoSitePlus; O15111; -.
DR   BioMuta; CHUK; -.
DR   EPD; O15111; -.
DR   MaxQB; O15111; -.
DR   PaxDb; O15111; -.
DR   PeptideAtlas; O15111; -.
DR   PRIDE; O15111; -.
DR   Ensembl; ENST00000370397; ENSP00000359424; ENSG00000213341.
DR   GeneID; 1147; -.
DR   KEGG; hsa:1147; -.
DR   UCSC; uc001kqp.4; human.
DR   CTD; 1147; -.
DR   DisGeNET; 1147; -.
DR   GeneCards; CHUK; -.
DR   H-InvDB; HIX0201495; -.
DR   HGNC; HGNC:1974; CHUK.
DR   HPA; CAB004240; -.
DR   HPA; CAB018564; -.
DR   HPA; HPA001402; -.
DR   MalaCards; CHUK; -.
DR   MIM; 600664; gene.
DR   MIM; 613630; phenotype.
DR   neXtProt; NX_O15111; -.
DR   OpenTargets; ENSG00000213341; -.
DR   PharmGKB; PA26510; -.
DR   eggNOG; KOG4250; Eukaryota.
DR   eggNOG; ENOG410XRMU; LUCA.
DR   GeneTree; ENSGT00820000127009; -.
DR   HOGENOM; HOG000038048; -.
DR   HOVERGEN; HBG018241; -.
DR   InParanoid; O15111; -.
DR   KO; K04467; -.
DR   OMA; FVLMDHI; -.
DR   OrthoDB; EOG091G02VC; -.
DR   PhylomeDB; O15111; -.
DR   TreeFam; TF324269; -.
DR   BRENDA; 2.7.11.10; 2681.
DR   Reactome; R-HSA-1169091; Activation of NF-kappaB in B cells.
DR   Reactome; R-HSA-1236974; ER-Phagosome pathway.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-1810476; RIP-mediated NFkB activation via ZBP1.
DR   Reactome; R-HSA-198323; AKT phosphorylates targets in the cytosol.
DR   Reactome; R-HSA-202424; Downstream TCR signaling.
DR   Reactome; R-HSA-2871837; FCERI mediated NF-kB activation.
DR   Reactome; R-HSA-445989; TAK1 activates NFkB by phosphorylation and activation of IKKs complex.
DR   Reactome; R-HSA-446652; Interleukin-1 signaling.
DR   Reactome; R-HSA-5357905; Regulation of TNFR1 signaling.
DR   Reactome; R-HSA-5357956; TNFR1-induced NFkappaB signaling pathway.
DR   Reactome; R-HSA-5602636; IKBKB deficiency causes SCID.
DR   Reactome; R-HSA-5603027; IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR).
DR   Reactome; R-HSA-5603029; IkBA variant leads to EDA-ID.
DR   Reactome; R-HSA-5607761; Dectin-1 mediated noncanonical NF-kB signaling.
DR   Reactome; R-HSA-5607764; CLEC7A (Dectin-1) signaling.
DR   Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer.
DR   Reactome; R-HSA-5676590; NIK-->noncanonical NF-kB signaling.
DR   Reactome; R-HSA-5684264; MAP3K8 (TPL2)-dependent MAPK1/3 activation.
DR   Reactome; R-HSA-933542; TRAF6 mediated NF-kB activation.
DR   Reactome; R-HSA-933543; NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10.
DR   Reactome; R-HSA-937039; IRAK1 recruits IKK complex.
DR   Reactome; R-HSA-937041; IKK complex recruitment mediated by RIP1.
DR   Reactome; R-HSA-975144; IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation.
DR   SABIO-RK; O15111; -.
DR   SignaLink; O15111; -.
DR   SIGNOR; O15111; -.
DR   ChiTaRS; CHUK; human.
DR   EvolutionaryTrace; O15111; -.
DR   GeneWiki; CHUK; -.
DR   GenomeRNAi; 1147; -.
DR   PRO; PR:O15111; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000213341; -.
DR   CleanEx; HS_CHUK; -.
DR   Genevisible; O15111; HS.
DR   GO; GO:0035631; C:CD40 receptor complex; ISS:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0008385; C:IkappaB kinase complex; TAS:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008384; F:IkappaB kinase activity; TAS:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0097110; F:scaffold protein binding; IDA:MGI.
DR   GO; GO:0009653; P:anatomical structure morphogenesis; TAS:ProtInc.
DR   GO; GO:0002479; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent; TAS:Reactome.
DR   GO; GO:0071276; P:cellular response to cadmium ion; IMP:CAFA.
DR   GO; GO:0034614; P:cellular response to reactive oxygen species; IMP:CAFA.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IDA:UniProtKB.
DR   GO; GO:0098586; P:cellular response to virus; IMP:CAFA.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; IMP:CAFA.
DR   GO; GO:0007252; P:I-kappaB phosphorylation; TAS:ProtInc.
DR   GO; GO:0006955; P:immune response; TAS:ProtInc.
DR   GO; GO:0006954; P:inflammatory response; TAS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; TAS:UniProtKB.
DR   GO; GO:0038061; P:NIK/NF-kappaB signaling; IMP:CAFA.
DR   GO; GO:0070423; P:nucleotide-binding oligomerization domain containing signaling pathway; TAS:Reactome.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; TAS:Reactome.
DR   GO; GO:1902741; P:positive regulation of interferon-alpha secretion; IMP:CAFA.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; TAS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IMP:CAFA.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0010803; P:regulation of tumor necrosis factor-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0010034; P:response to acetate; IEA:Ensembl.
DR   GO; GO:0043200; P:response to amino acid; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0033194; P:response to hydroperoxide; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:0009615; P:response to virus; TAS:UniProtKB.
DR   GO; GO:0007266; P:Rho protein signal transduction; IEA:Ensembl.
DR   GO; GO:0003009; P:skeletal muscle contraction; IEA:Ensembl.
DR   GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0051403; P:stress-activated MAPK cascade; TAS:Reactome.
DR   GO; GO:0051146; P:striated muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0035666; P:TRIF-dependent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IBA:GO_Central.
DR   InterPro; IPR022007; IKKbetaNEMObind.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF12179; IKKbetaNEMObind; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM01239; IKKbetaNEMObind; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Kinase; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN         1    745       Inhibitor of nuclear factor kappa-B
FT                                kinase subunit alpha.
FT                                /FTId=PRO_0000086011.
FT   DOMAIN       15    302       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      21     29       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      455    476       Leucine-zipper.
FT   REGION      738    743       NEMO-binding.
FT   ACT_SITE    144    144       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      44     44       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES      23     23       Phosphothreonine; by PKB/AKT1 and SGK1.
FT                                {ECO:0000269|PubMed:10485710,
FT                                ECO:0000269|PubMed:19088076}.
FT   MOD_RES     176    176       Phosphoserine; by MAP3K14.
FT                                {ECO:0000269|PubMed:9520446}.
FT   MOD_RES     179    179       O-acetylthreonine; by Yersinia yopJ.
FT                                {ECO:0000269|PubMed:17116858}.
FT   MOD_RES     180    180       Phosphoserine; by SGK1.
FT                                {ECO:0000269|PubMed:19088076}.
FT   VARIANT     126    126       S -> C (in dbSNP:rs34427437).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040565.
FT   VARIANT     155    155       V -> A (in dbSNP:rs2230803).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040566.
FT   VARIANT     268    268       V -> I (in dbSNP:rs2230804).
FT                                {ECO:0000269|PubMed:15164054,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:8777433,
FT                                ECO:0000269|PubMed:9244310,
FT                                ECO:0000269|PubMed:9252186,
FT                                ECO:0000269|PubMed:9813230}.
FT                                /FTId=VAR_021359.
FT   MUTAGEN      23     23       T->A: Loss of phosphorylation and
FT                                decrease of kinase activity.
FT                                {ECO:0000269|PubMed:10485710}.
FT   MUTAGEN      44     44       K->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:9244310,
FT                                ECO:0000269|PubMed:9346484}.
FT   MUTAGEN      44     44       K->M: Loss of autophosphorylation.
FT                                {ECO:0000269|PubMed:9244310,
FT                                ECO:0000269|PubMed:9346484}.
FT   MUTAGEN     176    176       S->A: Loss of phosphorylation and of
FT                                activity. {ECO:0000269|PubMed:9346484,
FT                                ECO:0000269|PubMed:9520446}.
FT   MUTAGEN     176    176       S->E: Full activation.
FT                                {ECO:0000269|PubMed:9346484,
FT                                ECO:0000269|PubMed:9520446}.
FT   MUTAGEN     179    179       T->A: No change in phosphorylation.
FT                                {ECO:0000269|PubMed:9520446}.
FT   MUTAGEN     180    180       S->A: No change in phosphorylation.
FT                                {ECO:0000269|PubMed:9520446}.
FT   CONFLICT    543    543       E -> G (in Ref. 2; AAC51671).
FT                                {ECO:0000305}.
FT   CONFLICT    604    604       L -> R (in Ref. 7; AAC50713).
FT                                {ECO:0000305}.
FT   CONFLICT    679    680       TS -> AY (in Ref. 7; AAC50713).
FT                                {ECO:0000305}.
FT   CONFLICT    684    684       P -> A (in Ref. 3; no nucleotide entry
FT                                and 7; AAC50713). {ECO:0000305}.
FT   CONFLICT    686    687       TS -> DL (in Ref. 7; AAC50713).
FT                                {ECO:0000305}.
FT   HELIX       735    737       {ECO:0000244|PDB:3BRT}.
FT   HELIX       741    743       {ECO:0000244|PDB:3BRT}.
SQ   SEQUENCE   745 AA;  84640 MW;  4EA55C6FFC66FA16 CRC64;
     MERPPGLRPG AGGPWEMRER LGTGGFGNVC LYQHRELDLK IAIKSCRLEL STKNRERWCH
     EIQIMKKLNH ANVVKACDVP EELNILIHDV PLLAMEYCSG GDLRKLLNKP ENCCGLKESQ
     ILSLLSDIGS GIRYLHENKI IHRDLKPENI VLQDVGGKII HKIIDLGYAK DVDQGSLCTS
     FVGTLQYLAP ELFENKPYTA TVDYWSFGTM VFECIAGYRP FLHHLQPFTW HEKIKKKDPK
     CIFACEEMSG EVRFSSHLPQ PNSLCSLVVE PMENWLQLML NWDPQQRGGP VDLTLKQPRC
     FVLMDHILNL KIVHILNMTS AKIISFLLPP DESLHSLQSR IERETGINTG SQELLSETGI
     SLDPRKPASQ CVLDGVRGCD SYMVYLFDKS KTVYEGPFAS RSLSDCVNYI VQDSKIQLPI
     IQLRKVWAEA VHYVSGLKED YSRLFQGQRA AMLSLLRYNA NLTKMKNTLI SASQQLKAKL
     EFFHKSIQLD LERYSEQMTY GISSEKMLKA WKEMEEKAIH YAEVGVIGYL EDQIMSLHAE
     IMELQKSPYG RRQGDLMESL EQRAIDLYKQ LKHRPSDHSY SDSTEMVKII VHTVQSQDRV
     LKELFGHLSK LLGCKQKIID LLPKVEVALS NIKEADNTVM FMQGKRQKEI WHLLKIACTQ
     SSARSLVGSS LEGAVTPQTS AWLPPTSAEH DHSLSCVVTP QDGETSAQMI EENLNCLGHL
     STIIHEANEE QGNSMMNLDW SWLTE
//
